Skip to main content Accessibility help
×
Home
  • Get access
    Check if you have access via personal or institutional login
  • Cited by 5
  • Print publication year: 2015
  • Online publication date: February 2015

18 - ADHD diagnostic and symptom assessment scales for adults

References

1. LaheyBB, ApplegateB, McBurnettK, et al. DSM-IV field trials for attention deficit hyperactivity disorder in children and adolescents. Am J Psychiatry. 1994;151(11):1673–85.
2. SpitzerRL, DaviesM, BarkleyRA. The DSM-III-R field trial of disruptive behavior disorders. J Am Acad Child Adolesc Psychiatry. 1990;29(5):690–7.
3. AdlerL, CohenJ. Diagnosis and evaluation of adults with attention-deficit/hyperactivity disorder. Psychiatr Clin North Am. 2004;27(2):187–201.
4. FaraoneSV. The scientific foundation for understanding attention-deficit/hyperactivity disorder as a valid psychiatric disorder. Eur Child Adolesc Psychiatry. 2005;14(1):1–10.
5. EpsteinJN, JohnsonDE, ConnersCK. Conners’ Adult ADHD Diagnostic Interview for DSM-IV. North Tonawanda, NY: Multi-Health Systems, Inc.; 2001.
6. FirstMB, GibbonsM, WilliamsJBW, SpitzerRL. SCID Screen Patient Questionnaire-Extended Version. North Tonawanda, NY: Multi-Health Systems, Inc.; 1997.
7. EpsteinJN, KollinsSH. Psychometric properties of an adult ADHD diagnostic interview. J Atten Disord. 2006;9(3):504–14.
8. MichelsonD, AdlerL, SpencerT, et al. Atomoxetine in adults with ADHD: two randomized, placebo-controlled studies. Biol Psychiatry. 2003;53(2):112–20.
9. ReimherrFW, MarchantBK, StrongRE, et al. Emotional dysregulation in adult ADHD and response to atomoxetine. Biol Psychiatry. 2005;58(2):125–31.
10. AdlerLA, SuttonVK, MooreRJ, et al. Quality of life assessment in adult patients with attention-deficit/hyperactivity disorder treated with atomoxetine. J Clin Psychopharmacol. 2006;26(6):648–52.
11. AdlerLA, LiebowitzM, KronenbergerW, et al. Atomoxetine treatment in adults with attention-deficit/hyperactivity disorder and comorbid social anxiety disorder. Depress Anxiety. 2009;26(3):212–21.
12. DurellT, AdlerL, WilensT, PaczkowskiM, SchuhK. Atomoxetine treatment for ADHD: younger adults compared with older adults. J Atten Disord. 2010;13(4):401–6.
13. SolantoMV, MarksDJ, WassersteinJ, et al. Efficacy of meta-cognitive therapy for adult ADHD. Am J Psychiatry. 2010;167(8):958–68.
14. KesslerRC, AdlerL, BarkleyR, et al. The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey Replication. Am J Psychiatry. 2006;163(4):716–23.
15. WilensTE, HaightBR, HorriganJP, et al. Bupropion XL in adults with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled study. Biol Psychiatry. 2005;57(7):793–801.
16. SpencerTJ, AdlerLA, WeislerRH, YouchaSH. Triple-bead mixed amphetamine salts (SPD465), a novel, enhanced extended-release amphetamine formulation for the treatment of adults with ADHD: a randomized, double-blind, multicenter, placebo-controlled study. J Clin Psychiatr. 2008;69(9):1437–48.
17. AdlerLA, SpencerTJ, BiedermanJ, et al. The internal consistency and validity of the Attention-Deficit/Hyperactivity Disorder Rating Scale (ADHD-RS) with adult ADHD prompts as assessed during a clinical treatment trial. J ADHD Relat Disord. 2009;1(1):14–24.
18. FirstMB, SpitzerRL, GibbonM, WilliamsJ. Structured Clinical Interview for DSM-IV-TR Axis I Disorders-Patient Edition (SCID-I/P). New York, NY: Biometrics Research Department, New York State Psychiatric Institute; 2002.
19. BarkleyRA. Barkley Adult ADHD Rating Scale-IV (BAARS-IV). New York, NY: Guilford Press; 2011.
20. BarkleyRA. Attention-Deficit Hyperactivity Disorder: A Handbook for Diagnosis and Treatment, 3rd edn. New York, NY: Guilford Press; 2005.
21. BrownTE. Brown Attention-Deficit Disorder Scales for Adolescents and Adults. San Antonio, TX: The Psychological Corporation; 1996.
22. RöslerM, RetzW, ThomeJ, et al. Psychopathological rating scales for diagnostic use in adults with attention-deficit/hyperactivity disorder (ADHD). Eur Arch Psychiatry Clin Neurosci. 2006;256(Suppl 1):i3–11.
23. KaufmanJ, BirmaherB, BrentD, et al. Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime Version (K-SADS-PL): initial reliability and validity data. J Am Acad Child Adolesc Psychiatry. 1997;36(7):980–8.
24. KooijJJS. Adult ADHD. Diagnostic Assessment and Treatment, 3rd edn. New York, NY: Springer; 2012
25. O’DonnellJP, McCannKK, PluthS. Assessing adult ADHD using a self-report symptom checklist. Psychol Rep. 2001;88(3 Pt 1):871–81.
26. DuPaulGJ, GeorgeJ, PowerTJ, AnastopoulosAD. ADHD Rating Scale–IV: Checklists, Norms, and Clinical Interpretation. New York, NY: Guilford Press; 1998.
27. FariesDE, YalcinI, HarderD, HeiligensteinJH. Validation of the ADHD Rating Scale as a clinician administered and scored instrument. J Atten Disord. 2001;5(2):107–15.
28. AdlerLA, SpencerT, FaraoneSV, et al. Training raters to assess adult ADHD: reliability of ratings. J Atten Disord. 2005;8(3):121–6.
29. SpencerTJ, AdlerLA, QiaoM, et al. Validation of the adult investigator symptom rating scale (AISRS). J Atten Disord. 2010;14(1):57–68.
30. BiedermanJ, MickE, SpencerT, et al. An open-label trial of OROS methylphenidate in adults with late-onset ADHD. CNS Spectr. 2006;11(5):390–6.
31. AdlerLA, SpencerT, BrownTE, et al. Once-daily atomoxetine for adult attention-deficit/hyperactivity disorder: a 6-month, double-blind trial. J Clin Psychopharmacol. 2009;29(1):44–50.
32. HerveyAS, EpsteinJN, CurryJF. Neuropsychology of adults with attention-deficit/hyperactivity disorder: a meta-analytic review. Neuropsychology. 2004;18(3):485–503.
33. BrownTE, LandgrafJM. Improvements in executive function correlate with enhanced performance and functioning and health-related quality of life: evidence from 2 large, double-blind, randomized, placebo-controlled trials in ADHD. Postgrad Med. 2010;122(5):42–51.
34. BrownTE, BramsM, GasiorM, et al. Clinical utility of ADHD symptom thresholds to assess normalization of executive function with lisdexamfetamine dimesylate treatment in adults. Curr Med Res Opin. 2011;27(Suppl 2):23–33.
35. BrownTE, HoldnackJ, SaylorK, et al. Effect of atomoxetine on executive function impairments in adults with ADHD. J Atten Disord. 2011;15(2):130–8.
36. Van VoorheesEE, HardyKK, KollinsSH. Reliability and validity of self- and other-ratings of symptoms of ADHD in adults. J Atten Disord. 2011;15(3):224–34.
37. WenderPH, ReimherrFW, WoodDR. Attention deficit disorder (‘minimal brain dysfunction’) in adults. A replication study of diagnosis and drug treatment. Arch Gen Psychiatry. 1981;38(4):449–56.
38. WenderPH. Attention-Deficit Hyperactivity Disorder in Adults. New York, NY: Oxford University Press; 1995.
39. KesslerRC, AdlerL, AmesM, et al. The World Health Organization Adult ADHD Self-Report Scale (ASRS): a short screening scale for use in the general population. Psychol Med. 2005;35(2):245–56.
40. KesslerRC, GreenJG, AdlerLA, et al. Structure and diagnosis of adult attention-deficit/hyperactivity disorder: analysis of expanded symptom criteria from the Adult ADHD Clinical Diagnostic Scale. Arch Gen Psychiatry. 2010;67(11):1168–78.
41. KesslerRC, AdlerLA, GruberMJ, et al. Validity of the World Health Organization Adult ADHD Self-Report Scale (ASRS) Screener in a representative sample of health plan members. Int J Methods Psychiatr Res. 2007;16(2):52–65.
42. BrodM, JohnstonJ, AbleS, SwindleR. Validation of the adult attention-deficit/hyperactivity disorder quality-of-life scale (AAQoL): a disease-specific quality-of-life measure. Qual Life Res. 2006;15(1):117–29.
43. MatzaLS, JohnstonJA, FariesDE, MalleyKG, BrodM. Responsiveness of the Adult Attention-Deficit/Hyperactivity Disorder Quality of Life Scale (AAQoL). Qual Life Res. 2007;16(9):1511–20.
44. LangrafJ. Monitoring quality of life in adults with ADHD : reliability and validity of a new measure. J Atten Disord. 2007;11:351 originally published online May 9, 2007, DOI: 10.1177/1087054707299400.
45. BarkleyR. Barkley Functional Impairment Scale (BFIS for Adults). New York, NY: Guilford Press; 2011.
46. The Canadian Attention Deficit Hyperactivity Disorder Resource Alliance (CADDRA). Weiss Functional Impairment Rating Scale Self-Report (WFIRS-S). http://www.caddra.ca/cms4/pdfs/caddraGuidelines2011WFIRS_S.pdf.
47. The Canadian Attention Deficit Hyperactivity Disorder Resource Alliance (CADDRA). Weiss Functional Impairment Rating Scale Self-Report (WFIRS-S) instructions. http://naceonline.com/AdultADHDtoolkit/assessmenttools/wfirs.pdf.
48. MurphyKR, AdlerLA. Assessing attention-deficit/hyperactivity disorder in adults: focus on rating scales. J Clin Psychiatry. 2004;65(Suppl 3):12–17.
49. ConnersCK, ErhardtD, SparrowE.Conners’ Adult ADHD Rating Scales. North Tonawanda, NY: Multi-Health Systems, Inc.; 1999.
50. SpencerT, BiedermanJ, WilensT, et al. A large, double-blind, randomized clinical trial of methylphenidate in the treatment of adults with attention-deficit/hyperactivity disorder. Biol Psychiatry. 2005;57(5):456–63.
51. BiedermanJ, MickE, SurmanC, et al. A randomized, placebo-controlled trial of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder. Biol Psychiatry. 2006;59(9):829–35.
52. AdlerLA, SpencerT, FaraoneSV, et al. Validity of pilot adult ADHD self-report scale (ASRS) to rate adult ADHD symptoms. Ann Clin Psychiatry. 2006;18(3):145–8.
53. AdlerLA, SpencerTJ, WilliamsDW, MooreRJ, MichelsonD. Long-term, open-label safety and efficacy of atomoxetine in adults with ADHD: final report of a 4-year study. J Atten Disord. 2008;12(3):248–53.